Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper; Wouters, Michel W. J. M.; Hilarius, Doranne L.; Haanen, John B.; Blank, Christian U.; Aarts, Maureen J. B.; van den Berkmortel, Franchette W. P. J.; de Groot, Jan-Willem B.; Hospers, Geke A. P.; Kapiteijn, Ellen; Piersma, Djura; van Rijn, Roos S.; Suijkerbuijk, Karijn P. M.; Blokx, Willeke A. M.; ten Tije, Bert-Jan J.; van der Veldt, Astrid A. M.; Vreugdenhil, Art; Boers-Sonderen, Marye J.; van den Eertwegh, Alfonsus J. M.

doi:10.1038/s41416-021-01312-1

Download PDF

Correction
Published: 15 March 2021

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten^1,2,
Michel W. J. M. Wouters^1,3,
Doranne L. Hilarius⁴,
John B. Haanen⁵,
Christian U. Blank^5,6,
Maureen J. B. Aarts⁷,
Franchette W. P. J. van den Berkmortel⁸,
Jan-Willem B. de Groot⁹,
Geke A. P. Hospers¹⁰,
Ellen Kapiteijn¹¹,
Djura Piersma¹²,
Roos S. van Rijn¹³,
Karijn P. M. Suijkerbuijk¹⁴,
Willeke A. M. Blokx¹⁵,
Bert-Jan J. ten Tije¹⁶,
Astrid A. M. van der Veldt ORCID: orcid.org/0000-0003-0446-1907¹⁷,
Art Vreugdenhil¹⁸,
Marye J. Boers-Sonderen¹⁹ &
…
Alfonsus J. M. van den Eertwegh²

British Journal of Cancer volume 124, page 1746 (2021)Cite this article

937 Accesses
1 Altmetric
Metrics details

Subjects

Melanoma

The Original Article was published on 26 January 2021

Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-01229-1, published online 26 January 2021

Since the publication of this paper, the authors have noticed an error in the Abstract where the value for the 2-year overall survival for patients receiving anti-PD-1 antibodies was incorrectly given as 85.4% (95% CI: 58.1–73.6) rather than the correct value of 65.4% (95% CI: 58.1–73.6). This has been corrected. The authors would like to apologise for this error, which does not alter the conclusions of the paper.

Author information

Authors and Affiliations

Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, The Netherlands
Jesper van Breeschoten & Michel W. J. M. Wouters
Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, Amsterdam, 1081HZ, The Netherlands
Jesper van Breeschoten & Alfonsus J. M. van den Eertwegh
Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, The Netherlands
Michel W. J. M. Wouters
Department of Pharmacy, Rode Kruis Ziekenhuis, Vondellaan 13, Beverwijk, 1942LE, The Netherlands
Doranne L. Hilarius
Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, The Netherlands
John B. Haanen & Christian U. Blank
Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, The Netherlands
Christian U. Blank
Department of Medical Oncology, Maastricht University Medical Centre, P. Debyelaan 25, Maastricht, 6229 HX, The Netherlands
Maureen J. B. Aarts
Department of Medical Oncology, Zuyderland Medical Centre Sittard, Dr. H. van der Hoffplein 1, Sittard-Geleen, 6162BG, The Netherlands
Franchette W. P. J. van den Berkmortel
Isala Oncology Center, Isala, Dokter van Heesweg 2, Zwolle, 8025AB, The Netherlands
Jan-Willem B. de Groot
Department of Medical Oncology, University Medical Centre Groningen, Hanzeplein 1, Groningen, 9713GZ, The Netherlands
Geke A. P. Hospers
Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, Leiden, 2333ZA, The Netherlands
Ellen Kapiteijn
Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, Enschede, 7512KZ, The Netherlands
Djura Piersma
Department of Internal Medicine, Medical Centre Leeuwarden, Henri Dunantweg 2, Leeuwarden, 8934AD, The Netherlands
Roos S. van Rijn
Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht, 3584CX, The Netherlands
Karijn P. M. Suijkerbuijk
Department of Pathology, Division of Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands
Willeke A. M. Blokx
Department of Internal Medicine, Amphia Hospital, Molengracht 21, Breda, 4818CK, The Netherlands
Bert-Jan J. ten Tije
Departments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, ‘s-Gravendijkwal 230, Rotterdam, 3015CE, The Netherlands
Astrid A. M. van der Veldt
Department of Internal Medicine, Maxima Medical Centre, De Run 4600, Eindhoven, 5504DB, The Netherlands
Art Vreugdenhil
Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, Nijmegen, 6525GA, The Netherlands
Marye J. Boers-Sonderen

Authors

Jesper van Breeschoten
View author publications
Search author on:PubMed Google Scholar
Michel W. J. M. Wouters
View author publications
Search author on:PubMed Google Scholar
Doranne L. Hilarius
View author publications
Search author on:PubMed Google Scholar
John B. Haanen
View author publications
Search author on:PubMed Google Scholar
Christian U. Blank
View author publications
Search author on:PubMed Google Scholar
Maureen J. B. Aarts
View author publications
Search author on:PubMed Google Scholar
Franchette W. P. J. van den Berkmortel
View author publications
Search author on:PubMed Google Scholar
Jan-Willem B. de Groot
View author publications
Search author on:PubMed Google Scholar
Geke A. P. Hospers
View author publications
Search author on:PubMed Google Scholar
Ellen Kapiteijn
View author publications
Search author on:PubMed Google Scholar
Djura Piersma
View author publications
Search author on:PubMed Google Scholar
Roos S. van Rijn
View author publications
Search author on:PubMed Google Scholar
Karijn P. M. Suijkerbuijk
View author publications
Search author on:PubMed Google Scholar
Willeke A. M. Blokx
View author publications
Search author on:PubMed Google Scholar
Bert-Jan J. ten Tije
View author publications
Search author on:PubMed Google Scholar
Astrid A. M. van der Veldt
View author publications
Search author on:PubMed Google Scholar
Art Vreugdenhil
View author publications
Search author on:PubMed Google Scholar
Marye J. Boers-Sonderen
View author publications
Search author on:PubMed Google Scholar
Alfonsus J. M. van den Eertwegh
View author publications
Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Alfonsus J. M. van den Eertwegh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Breeschoten, J., Wouters, M.W.J.M., Hilarius, D.L. et al. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis. Br J Cancer 124, 1746 (2021). https://doi.org/10.1038/s41416-021-01312-1

Download citation

Published: 15 March 2021
Version of record: 15 March 2021
Issue date: 11 May 2021
DOI: https://doi.org/10.1038/s41416-021-01312-1